The radiosynthesis of [18F]fluoroacetate by a Tracerlab MX synthesizer in Shin-Kong Memorial Hospital.

1Chi-Wei Chang, 2Wen-Sheng Huang, 3Tsung-Hsun Yu, 5Ching-Huang Lo, 3,4Skye Hsin-Hsien Yeh*

1 R&D department, Primo Biotechnology Co., Ltd., Taipei, Taiwan
2 Department of Nuclear Medicine, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan
3 School of Medicine, National Defense Medical Center, Taipei, Taiwan
4 Brain Research Center, National Yang Ming Chaio Tung University, Taipei, Taiwan5 Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan

This study poster was presented at 2024 Annual Conference of Society of Nuclear Medicine, Taiwan.

This study was designed to assess the potential of [18F]fluoroacetate([18F]FAC) as a PET imaging radiotracer applied to a pancreatic tumors in mouse model.

By using a Tracerlab MX synthesizer, the research team successfully synthesized a cGMP-level [18F]FAC at Shin-Kong Memorial Hospital, performing quality assurance testing to ensure its radiochemical purity and sterility. In vivo study results showed that compared to the traditionally used [18F]FDG, [18F]FAC could detect tumor xenografts two days earlier during the initial stage of tumor formation, although the visualization effect of [18F]FDG was more distinct in imaging. These findings confirmed not only the synthesis stability and radiochemical yield of [18F]FAC but also indicated its potential for exploring metabolic changes, making it suitable for long-term preclinical studies.

About Primo

Primo collaborates with both domestic and international partners to accelerate progress in precision oncology, leveraging its capabilities in drug development, clinical translation, and GMP manufacturing to support next-generation therapeutics. For more information, please follow Primo Biotech on Facebook and LinkedIn.